Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)

J. F. Kessler, S. E. Jones, N. Levine, P. J. Lynch, A. R. Booth, F. L. Meyskens

Research output: Contribution to journalArticlepeer-review


Retinoids, including isotretinoin, have demonstrated antiproliferative and antineoplastic activity in laboratory and clinical trials. In a phase II trial, 25 patients with extensive mycosis fungoides were evaluated for response to isotretinoin. There was a 44% (11 patients) objective clinical response rate with three clinical complete responses without concomitant evidence of pathologic clearing of the disease. An additional 24% (six patients) showed a minor degree of clinical improvement. The median time to response was two months (range, 0.5 to eight months) and the median response duration was eight months or longer (range, one to 25 months). Chronic toxic reactions consisted primarily of drying of the skin and mucous membranes and resulted in dose reduction in the majority of patients. It is concluded that isotretinoin produces significant clinical benefit to some patients with mycosis fungoides.

Original languageEnglish (US)
Pages (from-to)201-204
Number of pages4
JournalArchives of Dermatology
Issue number2
StatePublished - Mar 24 1987


Dive into the research topics of 'Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)'. Together they form a unique fingerprint.

Cite this